key: cord-0781801-ebpmkaao authors: Hamdan, Hamdan; Hashmi, Shahrukh K.; Lazarus, Hillard; Gale, Robert Peter; Qu, Wenchun; El Fakih, Riad title: Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome? date: 2020-08-13 journal: Blood Reviews DOI: 10.1016/j.blre.2020.100742 sha: 6bd987d38a11c9d20d1591a4cb9a96f50bec1797 doc_id: 781801 cord_uid: ebpmkaao Abstract Mesenchymal stromal cells (MSC) have immune regulatory and tissue regenerative properties. MSCs are being studied as a therapy option for many inflammatory and immune disorders and are approved to treat acute graft-versus-host disease (GvHD). The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and associated coronavirus infectious disease-19 (COVID-19) has claimed many lives. Innovative therapies are needed. Preliminary data using MSCs in the setting of acute respiratory distress syndrome (ARDS) in COVID-19 are emerging. We review mechanisms of action of MSCs in inflammatory and immune conditions and discuss a potential role in persons with COVID-19. Mesenchymal stromal cells (MSCs) are a promising therapy of inflammatory and immune disorders because of their immune modulatory properties 1, 2 . MSCs , by interacting with the innate immune system, sense inflammatory signals and exert antiand pro-inflammatory roles making them an option to treat auto-and allo-immune processes 3, 4 . MSCs are used to treat some diseases with promising results [5] [6] [7] . There are recent reports of therapy of COVID-19-related severe acute respiratory syndrome (ARDS) with MSCs 8, 9 . ARDS is the leading cause of death in COVID-19. It is characterized by acute onset with bilateral lung infiltrates, no evidence of elevated left atrial pressure and arterial oxygen tension to inspired oxygen fraction (PaO2/FiO2) < 200 mmHg 10 . The cytokine storm caused by the viral infection probably precipitates COVID-19-associated ARDS. Avoiding this storm using the anti-inflammatory properties of MSCs may be effective 9, 11, 12 . We review data on anti-inflammatory activity of MSCs and discuss mouse and human studies in COVID-19. Accurate identification of MSCs is challenging and imprecise 13, 14 20, 21 . MSCs-produced interleukin-6 (IL-6) and hepatocyte growth factor (HGF) stimulate monocytes to secrete interleukin-10 (IL-10) at high concentrations. These effects reduce IL-12p70, tumor necrosis factor-alpha (TNF-a), interleukin-17 (IL-17), high levels of major histocompatibility complex (MHC) class II antigens, CD45R and CD11b which suppress T-cells. This action of MSCs is independent of FoxP3+ Tregs and inhibits differentiation of dendritic cells (DCs) to a type I phenotype 15, [22] [23] [24] . Also, Tregs are stimulated by MSCs and achieve immune homeostasis by suppressing autoimmunity 25, 26 . In preclinical models, treatment of MSCs with interferon-gamma (IFN-γ) enhances their anti-inflammatory effects. Incubation with muramyl dipeptide (MDP) increases their ability to suppress mononuclear cell proliferation and reduce inflammation 27, 28 . Additionally, MSCs produce LL37 (a 37 amino acid cathelicidin antimicrobial peptide), a potent anti-microbial that kills bacteria and viruses 18 . As such regulatory T-cells resulting in anti-inflammatory effects in diverse models of acute inflammation in different tissues and organs [29] [30] [31] [32] [33] [34] [35] [36] . Additionally, pre-stimulation of MSCs with specific TLR-ligands could be a priming step to modulate their function to achieve a desired effect in specific viral infections such as with SARS-CoV-2. Exosomes, apoptotic bodies and micro-vesicles, are formed by budding from the endosomes and other membranes of MSCs and released into the extra-cellular space 39, 40 . Considerable data indicate MSC-exosomes contain molecules (tetraspanins, heat Immune modulatory effects of MSCs offer an attractive potential therapy for several reasons including safety, availability, ex vivo expandability, and ease of in vitro modification to produce diverse effects. However, there are many unanswered questions such as best tissue source of MSCs (bone marrow, fat, placenta, dental pulp, etc.), best dose, route, frequency, recipient age-dependency groups, interaction with other therapies and the long term effects [45] [46] [47] [48] [49] [50] [51] . There are few data of safety and efficacy of MSCs in humans 52 . In a transplant study investigator infused culture-expanded MSCs with HLA-identical sibling-matched hematopoietic stem cells in 46 subjects with hematologic cancers. There were no adverse effects 53 . A phase-3 trial comparing MSCs or placebo in subjects with corticosteroid refractory acute GvHD showed no benefit 54, 55 . A single arm trial of ex vivo expanded MSCs for corticosteroid refractory acute GvHD in children had a 70% overall response rate compared with a pre-specified target of 45% 56 . These trials were neither blinded nor placebo-controlled. A meta-analysis suggested safety and efficacy of MSCs in acute GvHD 57 . Based on these data MSCs were approved to treat gastrointestinal GvHD in children in Canada and New Zealand but not in the US or EU 58 . Studies using MSCs for ARDS report safety but little efficacy 59, 60 . A meta-analysis suggested efficacy of MSCs in inflammatory bowel disease 61 . A search of ClinicalTrials.gov identified 282 studies of MSCs in diverse settings. Table 1 summarizes these data. Because ARDS in persons with COVID-19 is thought to result from cytokine release syndrome (CRS) studies of interventions to moderate this response seem reasonable. Corticosteroids were used in several uncontrolled studies but a recent meta-analysis reported them ineffective with prolonged virus clearing and other adverse events in severe coronavirus infections 69 . MSCs in the lung release anti-inflammatory mediators responsible for ameliorating respiratory viral-induced lung injuries 70, 71 . In an uncontrolled study investigators gave MSCs to 7 subjects with COVID-19-related pneumonia and results compared with 3 non-randomized, non-concurrent controls 9 . Giving MSCs to humans seems safe 8, 9, 54, 56, 61, 72 . A meta-analysis with data of > 1000 subjects reported only transient fever 74 . Reports of using MSCs for diverse setting including heart failure, kidney transplant and multiple sclerosis report few adverse events [75] [76] [77] [78] . MSCs products are diverse with multiple potential sources, production methods and delivery routes complicating critical analyses of safety. Serious adverse events including thrombosis, embolization and death are reported with some products in animals and humans but at a low frequency [79] [80] [81] [82] [83] . MSCs are an attractive potential therapy of diverse diseases including ARDS in persons with COVID-19. Several trials of MSCs are ongoing. Preliminary studies report favorable effects but have severe methodological limitations precluding critical analyses ( Table 2 ). There are several unanswered questions: (1) the best donor; (2) source; (3) dose, route and frequency; (4) fresh or cryopreserved; (5) expanded or not; (6) when to begin therapy and others. These questions can only be answered in controlled trials. Mesenchymal stromal cells: sensors and switchers of inflammation Immunomonitoring of MSC-treated GvHD patients reveals only moderate potential for response prediction but indicates treatment safety Mesenchymal stromal cells: new directions Multipotent mesenchymal stromal cells and the innate immune system Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis Mesenchymal stem cells as therapeutics Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia Acute respiratory distress syndrome: pathophysiology and therapeutic options Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: The case for compassionate use The exciting prospects of new therapies with mesenchymal stromal cells Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections Concise review: mesenchymal stem (stromal) cells: biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion Aging of bone marrow-and umbilical cordderived mesenchymal stromal cells during expansion The MSC curtain that stops the immune system TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity Mesenchymal stromal cellderived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages Umbilical cordderived mesenchymal stem cells instruct monocytes towards an IL10-producing phenotype by secreting IL6 and HGF Functional specificity for high-level linguistic processing in the human brain Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle Foxp3 occupancy and regulation of key target genes during T-cell stimulation Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) Pretreatment with models of colitis Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2 Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice Mitochondrial transfer from bone-marrowderived stromal cells to pulmonary alveoli protects against acute lung injury Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes Prevention of LPSinduced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1 Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2, 3-dioxygenase-1 via interferon-beta and protein kinase R Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential Standardization of sample collection, isolation and analysis methods in extracellular vesicle research Role of cell-matrix interactions on VIC phenotype and tissue deposition in 3D PEG hydrogels Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia Mesenchymal stem cells secrete immunologically active exosomes Microvesicles derived from human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19 Effective treatment of steroid and therapy-refractory acute graft-versushost disease with a novel mesenchymal stromal cell product (MSC-FFM) Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graftversus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition The potential of mesenchymal stromal cells as treatment for severe steroidrefractory acute graft-versus-host disease: a critical review of the literature Heterogeneity in studies of mesenchymal stromal cells to treat or prevent graft-versus-host disease: a scoping review of the evidence Clinical use of mesenchymal stromal cells in the treatment of acute graft-versus-host disease Mesenchymal stromal cells for acute graftversus-host disease: response at 1 week predicts probability of survival Emerging Therapeutic Approaches for Multipotent Mesenchymal Stromal Cells (MSCs) Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease Survival after mesenchymal stromal cell therapy in steroidrefractory acute graft-versus-host disease: systematic review and meta-analysis Canada approves stem cell product Treatment of acute respiratory distress syndrome with allogeneic adiposestem cells: a randomized, placebo-controlled pilot study Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial Mesenchymal stem cell therapy for inflammatory bowel disease: a systematic review and metaanalysis Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice Keratinocyte growth factor gene delivery via mesenchymal stem cells protects against lipopolysaccharide-induced acute lung injury in mice Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the antiinflammatory protein TSG-6 Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37 Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19 Canadian Critical Care Trials G. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials Stem cell therapy for multiple sclerosis Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis Korean deaths spark inquiry: cases highlight the challenge of policing multinational trade in stem-cell treatments Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism Procoagulant activity of human mesenchymal stem cells